(Boursier.com) — Aelis Farma is developing two drug candidates, AEF0117 and AEF0217, which target a specific element of the brain: the CB1 neurotransmitter receptor of the endocannabinoid system. In doing so, biotech is targeting treatments against disorders due to cannabis for the 1st molecule and to Trisomy 21 for the 2nd.
©2022 Boursier.com